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SUMMARY
Background
Osteoporosis is a recognized complication of inflammatory bowel dis-
ease (IBD).
Aim
To investigate the role of environmental factors and vitamin D receptor
(VDR) variants on the prevalence of osteoporosis.
Methods
DEXA scans and case note review were performed on 440 IBD patients
from 1997 to 2006. All the IBD patients and 240 healthy controls were
genotyped for VDR variants Taq-1 and Apa-1 using PCR-RFLP.
Results
Osteoporosis and osteopenia rates were 15% and 18% for IBD, 16% and
18% for Crohn’s disease (CD) and 13% and 19% for ulcerative colitis,
respectively. On univariate analysis of the CD patients, low body mass
index (BMI, <18.5) and smoking status (P = 0.008 and 0.005 respec-
tively) were associated with osteoporosis and osteopenia. Low BMI was
also associated with osteoporosis on multivariate analysis in CD
(P = 0.021, OR 5.83, CI 1.31–25.94). No difference was observed
between Taq-1 and Apa-1 VDR polymorphisms in IBD, CD, ulcerative
colitis and healthy controls. However, CD males were more likely to
carry the variant Taq-1 polymorphism than healthy controls males
(P = 0.0018, OR 1.94, CI 1.28–2.92) and female CD patients (P = 0.0061,
OR 1.60, CI 1.17–2.44).
Conclusions
In this well-phenotyped cohort of IBD patients, a relatively low preva-
lence of osteoporosis was observed. Low BMI was the only independent
risk factor identified to be associated with osteoporosis.
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INTRODUCTION
The inflammatory bowel diseases (IBD), Crohn’s dis-
ease (CD) and ulcerative colitis (UC) are immune-
mediated diseases that result in chronic, relapsing
inflammation of the gastrointestinal (GI) tract. These
diseases occur in genetically susceptible individuals
who are exposed to as yet poorly defined environ-
mental stimuli.1, 2
Osteoporosis is defined by the World Health Orga-
nisation (WHO) as: ‘A disease characterized by low
bone mass and micro architectural deterioration of
bone tissue, leading to enhanced bone fragility and a
consequent increase in fracture risk.’3 The estimated
prevalence of osteoporosis in the IBD population
ranges widely from 13% to greater than 50%.4–7 This
complication has important implications in terms of
morbidity and population-based studies from Notting-
ham, UK have shown a 60% increased risk of frac-
ture in IBD patients.5
The aetiology of low bone mineral density (BMD) in
IBD is multifactorial. Risk factors include low body
mass index (BMI).4, 8, 9 Recent data from England are
pertinent. Bartram et al. in Newcastle observed that CD
patients with osteoporosis had a mean BMI of 22 com-
pared with those without osteoporosis where the BMI
was 25 (P < 0.0001).4 A number of studies have shown
that corticosteroid use is also a risk factor for the
development of osteoporosis in patients with
IBD6, 7, 10, 11 and other factors that include smoking,
hypogonadism, increased secretion of osteoclast stimu-
lating cytokines, calcium and vitamin D deficiency,
disease location and duration have been impli-
cated.4, 7–14
Twin studies have suggested that up to 80% of a
patient’s BMD is genetically determined.15 In view of
its chromosomal location and function, there has been
sustained interest in the contribution of germline vari-
ation of the vitamin D receptor (VDR) gene. The VDR
gene is located within the IBD2 susceptibility locus on
chromosome 12 and it spans at least 105 kb.16–18 It
encodes a steroid receptor that mediates the effects of
1,12(OH)2 vitamin D3 by regulating the transcription
of cellular genes.19 The gene plays a well-described
role in skeletal metabolism but has also been shown
to have immunomodulatory effects as well as possible
roles in the growth of cancer cells and in insulin
secretion.20
The index study implicating VDR polymorphisms
in the regulation of bone density published in Nature
in 1994 suggested that the Bsm-1 variant of the
VDR gene in intron 8 conferred 75% of the genetic
variability of BMD; however, subsequently genotyp-
ing errors were identified and the results of this
study were modified.21 Two other VDR polymor-
phisms, Apa-1 and Taq-1 were found to be in strong
linkage disequilibrium with the original Bsm-1 vari-
ant and the Bsm-1–Apa-1–Taq-1 haplotype was
shown to have a moderate association with osteopo-
rosis.22, 23
More recently, the contribution of the VDR gene
was studied in comprehensive detail by Fang et al.
who observed a modest association between promoter
variation and 3¢ untranslated haplotypes and fracture
risk.16 These data contrast with data from a large par-
ticipant level meta-analysis of European patients,
where no association was observed between low BMD
and any of the VDR variants examined (Cdx-2, Fok-1,
Bsm-1, Apa-1, Taq-1).24
In a cohort of 245 CD patients from Newcastle, UK,
no association was observed between VDR variants
Fok-1 and Taq-1 and low BMD25; however, in a fur-
ther cohort of CD patients from Oxford, UK, there were
more VDR, Taq-1 homozygotes in the CD cohort when
compared with a healthy control population.26
The aims of the present study were to investigate
the prevalence of osteoporosis in our IBD cohort, and
to evaluate the contribution of specific environmental
and genetic factors on the development of osteoporosis
in this IBD population.
METHODS
Patients and controls
Four hundred and forty IBD patients attended the
Western General Hospital, Edinburgh and had demo-
graphic data collected and DNA stored as part of the
IBD database. All the patients selected had a confirmed
diagnosis of IBD, using the Lennard–Jones criteria.27
All had undergone at least one DEXA scan. Patients
under the age of 20 at the time of the DEXA scan
were excluded. For each patient, the following data
were generated: age, gender, age at diagnoses, disease
duration (in years), BMI, azathioprine therapy, inflix-
imab therapy, smoking status, family history, surgery,
the location of disease at diagnosis and behaviour of
disease at 5 years follow-up using Montreal classifica-
tion.28 Two hundred and eighty-six CD patients and
154 UC patients were recruited (Table 1).
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In all 45 osteoporotic CD patients and an age- and
gender-matched group of 45 non-osteoporotic CD
patients, a case note review was undertaken to calcu-
late the number of months each patient had spent on
corticosteroids. For the genetic study, the healthy
control population comprised 240 individuals recruited
from the Blood Transfusion Donor register and healthy
staff of the GI department of the WGH, all without GI
pathology. Informed consent was obtained from all
patients and controls – Lothian Local Research Ethics
Committee LREC 2000 ⁄4 ⁄192.
Bone mineral density measurement
DEXA scans were performed between 1997 and 2006
using a Hologic QDR4500A machine (Syngene, Cam-
bridge, UK) at the left hip, left femoral neck and the
lumbar spine on an anterior projection. The T-score at
the lumbar spine was selected for analysis as tight cor-
relation was observed between T-scores from the femo-
ral neck and lumbar spine-median T-score at the hip
)0.80, median T-score at the lumbar spine )0.94, r2 =
0.410, P < 0.001. Using the WHO criteria, osteoporosis
Table 1. Demographics of the Crohn’s disease (CD), ulcerative colitis (UC) and control cohorts
CD (n = 286) UC (n = 154) Controls (n = 240)
Gender (M:F) 107:179 74:79 118:122
Age at diagnosis (years) 31.9 39.7 40.2
Disease duration (years) 15.7 11.8
Montreal location at diagnosis (CD)
L1 (terminal ileum) 89
L2 (colonic) 94
L3 (ileo-colonic) 57
L4 (upper GI, proximal to terminal ileum) 8
L1 + L4 13
L2 + L4 3
L3 + L4 10
Oral Only 3
Montreal behaviour at 5 years
B1 (inflammatory) 140
B2 (stricturing) 43
B3 (penetrating) 42
B1P (inflammatory + perianal) 28
B2P (structuring + perianal) 3
B3P (penetrating + perianal) 7
Montreal at diagnosis (UC)
E1 (proctitis) 38
E2 (distal to splenic flexure) 61
E3 (extensive) 33
Current or ex-smoker 170 78
Never smoked 114 76
Normal (BMI = 18.5–24.9) 150 66
Underweight (BMI < 18.5) 9 1
Overweight (BMI > 24.9) 112 73
Surgery
Yes 166 20
No 117 134
Azathioprine treated
Yes 140 87
No 120 61
Infliximab treated
Yes 44 4
No 240 150
Full demographic data were available on 91% of the CD patients and 85% of the UC patients.
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was defined as a T-score of below )2.5 and osteopenia
when the T-score was between )1.0 and )2.5.3
Vitamin D receptor genotyping
Genomic DNA was extracted from peripheral venous
blood by a modified salting-out technique, and re-
suspended in 1· TE [10 mM Tris (pH 8.0), 1 mM EDTA
(pH 8.0)] at a final concentration of 100 ng ⁄lL.29 VDR
Taq-1 (rs17880019) and Apa-1 (rs17879735) genotyp-
ing was carried out using restriction digestion polymer-
ase chain reaction (PCR). The primers used were forward
5¢-CAGAGCATGGACAGGGAGCAA-3¢, back 5¢-CAC-
TTCGAGCACAAGGGGCGTTAG-3¢. PCR conditions were
as follows – initial denaturation at 94 C for 4 min fol-
lowed by 33 cycles of (94 C for 50 s, 64 C for 60 s,
followed by 72 C for 90 s) and a final extension at
72 C for 8 min and 30 s. Ten microlitres of PCR prod-
uct was then added to 10 lL of Taq-1 or Apa-1 digest
mixture and incubated at 65 C overnight. The digestion
products were then separated on 1.5% agarose gel with
ethidium bromide. The gel was visualized on Genege-
nius Bioimager (Syngene) with GENESNAP software using
ultraviolet light. The images were recorded digitally.
Statistical analysis
Data were compared using the chi-squared test or when
appropriate Fisher’s exact test using MINITAB software
(Minitab Ltd, Coventry, UK). The Mann–Whitney U-test
was used to compare nonparametric BMD data. To assess
differences between steroid dosages in the osteoporotic
and non-osteoporotic groups, an unpaired t-test with
Welch correction was used. To identify significant inde-
pendent variables associated with phenotype, multivariate
logistic regression analysis was carried out. Each single
nucleotide polymorphism (SNP) was analysed for associa-
tion with IBD overall, CD, UC and disease phenotype and
allele frequencies were determined for each polymor-
phism. In the control group, each allele was in Hardy–
Weinberg equilibrium. HAPLOVIEW software was used to
estimate haplotypes (Broad Institute of MIT and Harvard,
Boston, MA, USA). A P < 0.05 was considered significant.
RESULTS
Prevalence of osteoporosis and osteopenia
When all of the 440 IBD patients were investigated,
15% were osteoporotic, 18% had osteopenia and 67%
had normal T-scores at their lumbar spine (Figure 1).
In the CD patients, 16% were osteoporotic, 18% were
osteopenic and 66% had normal T-scores at their
lumbar spine and in the UC patients, 13% were osteo-
porotic, 19% were osteopenic and 68% had a normal
T-score.
Risk factors for reduced BMD
In CD patients, osteoporosis was associated with low
BMI (<18.5) – 44% of the low BMI patients had osteo-
porosis compared with 14% of the patients with a nor-
mal BMI who had osteoporosis, P = 0.048, OR 4.9 CI
1.2–19.8. A linear correlation between T-score at the
vertebral spine and BMI was observed in patients with
CD (r2 = 0.034, P = 0.0009) (Figure 2). When BMD was
compared with BMI, again a linear correlation was
observed (P = 0.0362).
Further analysis was carried out to include CD
patients at increased risk of fracture – those with oste-
oporosis and osteopenia. Low BMI (P = 0.0008) and
history of being a current or ex-smoker (P = 0.005)
were associated with osteoporosis and osteopenia
(Table 2). No association was observed between the
number of months a CD patient was on corticosteroid
therapy and osteoporosis. Osteoporotic CD patients had
a median of 30.4 months of corticosteroid therapy and
the non-osteoporotic CD patients had a median of
29.5 months of corticosteroid therapy (P = 0.92). No
phenotypic associations were observed with osteoporo-
sis in the UC cohort.
0% 
IBD CD UC 
10% 
20% 
30% 
40% 
50% 
60% 
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90% 
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Osteoporosis Osteopenia Normal
Figure 1. Low prevalence rates of osteoporosis and oste-
openia were observed in patients with inflammatory
bowel disease (IBD), Crohn’s disease (CD) and ulcerative
colitis (UC).
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Logistic regression analysis of the CD patients was
performed using a model that considered BMI groups,
smoking status, Montreal location, family history, sur-
gery, infliximab treatment, azathioprine treatment,
gender and Montreal behaviour at 5 years follow-up,
with the outcome being osteoporosis in patients with
CD. Low BMI (<18.5) was independently associated
with osteoporosis (P = 0.021, OR 5.83, CI 1.31–25.94).
Using this model, the percentage variance of osteopo-
rosis explained by BMI was 8.41%, being a current or
ex-smoker was 1.63%, female gender was 0.92%, ileal
disease location was 0.87%, exposure to azathioprine
was 0.52% and exposure to infliximab therapy was
0.42%. When cumulative corticosteroid doses were
added to the analysis, increased corticosteroid intake
contributed 0.4% to the variance of BMD.
Genotype results
When allelic frequencies of the VDR Apa-1 variant
were examined, there was no difference among
patients with IBD (45.8%), CD (45.3%), UC (46.7%) and
the control group (46.6%) (P > 0.7) (Table 3). When
the CD patients were split into those with and without
osteoporosis, there was also no difference in allelic
frequencies of the Apa-1 variant (45.7% osteoporosis
Figure 2. Body mass index (BMI) plotted against T-scores at
the lumbar spine of patients with Crohn’s disease. A linear
correlation was observed between T-scores at the vertebral
spine and BMI in patients with Crohn’s disease (n = 286).
Table 2. Analysis of the effect of phenotypic variables on the prevalence of osteoporosis and osteopenia in Crohn’s disease
(CD) patients
Phenotype Total n Osteoporosis and osteopenia % (n) P-value OR (CI)
BMI
Underweight BMI < 18.5 ⁄normal 9 ⁄ 150 88.9 (8) ⁄ 33.3 (50) 0.0008 16 (2–93)
Azathioprine treated
Yes ⁄no 136 ⁄ 119 34.6 (47) ⁄ 34.5 (41) 0.99 1.0 (0.5–1.8)
Infliximab treated
Yes ⁄no 44 ⁄ 240 45.5 (20) ⁄ 32.1 (77) 0.086 1.8 (0.9–3.4)
Family history*
Yes ⁄no 55 ⁄ 229 32.7 (18) ⁄ 34.5 (79) 0.80 0.9 (0.5–1.7)
Surgery
Yes ⁄no 166 ⁄ 117 37.3 (62) ⁄ 29.9 (35) 0.19 1.4 (0.8–2.3)
Gender
Male ⁄ female 107 ⁄ 178 39.6 (42) ⁄ 30.3 (54) 0.11 1.5 (0.9–2.5)
Smoking status
Current and ex ⁄never 170 ⁄ 114 41.3 (69) ⁄ 21.9(28) 0.005 2.1 (1.2–3.6)
Montreal location
L1 and L4 ⁄ L2 100 ⁄ 94 33 (33) ⁄ 34 (32) 0.88 1.0 (0.5–1.7)
L1 ⁄ L2 89 ⁄ 94 29.2(26) ⁄ 36.2 (34) 0.32 0.7 (0.4–1.4)
Montreal behaviour at 5 years
B1 ⁄B2 and B3 140 ⁄ 85 32.1(45) ⁄ 34.1 (29) 0.70 0.9 (0.5–1.6)
BMI, body mass index.
* Having one or more first degree relative with CD or UC.
 Surgery due to intra-luminal complication of CD or UC.
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compared with 42.9% non-osteoporosis, P = 0.72).
When the controls and patients were analysed by gen-
der, there was no significant difference among all of
the disease groups.
There was no association among the allelic fre-
quencies of the VDR Taq-1 SNP and IBD (40.1%), CD
(39.6%), UC (41.2%) and control populations (37.6%)
(P > 0.35), nor with osteoporosis in the CD cohort
(44% osteoporotic compared with 38.7% non-osteo-
porotic, P = 0.40). However, when allelic frequencies
of Taq-1 variants were examined in males and
females in the CD patients, there was a higher fre-
quency of variants in the male CD population (49.4%
vs. 36.7%, P = 0.0061, OR 1.69, CI 1.2–2.4). There
were also more Taq-1 variants in the male IBD, UC
and CD population compared with the male controls
34.2% healthy controls, 47.8% IBD (P = 0.003),
45.6% UC (P = 0.029) and 49.4% CD (P = 0.0017). No
genotypic or VDR Apa-1–Taq-1 haplotype associa-
tions were observed and no phenotypic associations
were observed.
DISCUSSION
Our retrospective data show that in this well-pheno-
typed cohort of IBD patients, relatively low levels of
osteoporosis and osteopenia were observed. Low BMI
was a robust predictor of osteoporosis. VDR variants
were not associated with osteoporosis; however,
intriguing gender-specific differences were observed.
The prevalence of osteoporosis in our CD (16%) and
UC (13%) population is in line with recent CD data
published from Newcastle, UK, where 11.6% of CD
patients were osteoporotic at either the lumbar spine
or femoral neck.4 The data are also comparable to data
from London, wherein patients with CD and UC the
incidence of osteoporosis of the vertebrae and the hip
was between 17% and 28%.30 There are, however,
studies from Israel where 42% of the patients had
osteoporosis14 and Cardiff where 31% of IBD patients
were osteoporotic.6
Patient selection bias may have a part to play, as
access to DEXA scanning varies considerably amongst
gastroenterologists. Our cohort of patients represent
essentially an unselected group of IBD patients from
the Edinburgh region. Our access to DEXA scans is
good, allowing physicians to check bone density in
the majority of IBD patients. In other centres, with
more limited resources, patients need to be prioritized
on the basis of clinical suspicion, and of disease
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severity and this may explain why the osteoporosis
levels are lower than those reported in this series.
In the same context, it is noteworthy that DEXA
scans in our cohort were performed closer to the date
of diagnosis compared with previous studies. Thirty-
two per cent of patients had their DEXA scan within
2 years of diagnosis and the median duration to the
first DEXA was 6 years. As the median age of diagno-
sis of IBD was 29.5 years, this cohort also represents a
younger population of IBD patients compared with
previous series. Our series also includes substantially
more patients than previous studies and this may
result in a more accurate estimation of the prevalence
of osteoporosis.
Low BMI was the strongest risk factor for osteoporo-
sis in our CD population, consistent with data from a
number of previous studies.4, 6, 8, 9 Despite only 3% of
patients having a BMI of less than 18.5, this was a sig-
nificant risk factor when logistic regression analysis
was undertaken. Using a multivariate model, variance
in BMI accounted for approximately 8.4% of the vari-
ance in BMD, a percentage lower than that suggested
by previous studies.4 However, it is worth noting that
overall only 13% of the variance in BMD was
explained by the environmental factors we have stud-
ied (including corticosteroid dose). These data would
suggest that, in our cohort, there are either other
unidentified critical environmental modifiers, or a crit-
ically important genetic component involved in deter-
mining BMD.
Increasing data are emerging both in patients with
IBD and in the healthy population that low BMI is a
significant independent risk factor for osteoporosis. In
a recent study of postmenopausal women in the USA,
Asomaning et al. observed a significant linear trend
across BMI categories with those with the lowest BMI
having the lowest BMD.31 The authors went on to
evaluate BMI as a continuous variable and observed a
decrease of 12% in BMD for each point decrease in
BMI. Low BMI has also been observed to predict risk
of hip fracture even after adjustment for BMD. In a
meta-analysis of 60 000 patients from 11 prospective
studies, the relative risk of fracture rose from 1.4 in
females with a BMI of 20 to 2.2 in females with a BMI
of 15.32
In this study, being a current or ex-smoker was also
associated with osteoporosis and osteopenia on uni-
variate analysis. The mechanisms underlying smoking-
associated bone loss and fracture risk remain poorly
understood and previous studies have suggested that
the effect of smoking appears to be dose-dependent,
and may be reversible.33 Smoking was not an indepen-
dent risk factor in the multivariate analysis, however,
suggesting that it plays a smaller role than low BMI in
determining BMD in the present cohort.
No association was observed between corticosteroid
use and osteoporosis when the osteoporotic CD
patients were compared with a matched non-osteopo-
rotic CD group. Although the role of corticosteroids in
the development of osteoporosis in patients with IBD
remains controversial, this result is in line with previ-
ous data published from our centre in 1994 where low
bone mineralization was observed in patients with CD
at diagnosis and prior to any corticosteroid therapy.34
Collating cumulative steroid exposure retrospectively
by case notes analysis is difficult. Our design has
allowed us to address this question to a similar extent
to previous studies, but we acknowledge this as a
potential limitation of the present study and we feel
strongly that further prospective studies are required.
In this study, we also did not collate data on the use
of bisphosphonates; however, we sought to minimize
this potential confounding factor by studying a young
cohort and using the index DEXA scan for analysis.
When the VDR variants Apa-1 and Taq-1 were
examined in our cohort of IBD patients, no association
was observed between osteoporosis and these variants.
Our results are consistent with data from Newcastle
where in patients with CD no association was observed
between VDR variants Taq-1 and Fok-1 and osteopo-
rosis.25 Results from both Newcastle and our data are
also consistent with a population based European
meta-analysis of 26 242 patients where no association
was observed between any of the five VDR variants
that were examined and low BMD.24
Although Fang et al. did not observe an association
between VDR variants and low BMD, they did observe
an association with fracture risk and the authors went
on to provide functional data showing reduced VDR
expression in variant reporter assays and increased
mRNA degradation.16 They further speculated that these
variants may alter fracture risk by modifying bone
micro-architecture rather than influencing BMD. Frac-
ture incidences were not measured in this study and it
may be that new imaging techniques will allow investi-
gators to assess better bone micro-architecture rather
than BMD alone to determine the fracture risk better.
Interestingly in our sub-group analysis, we
observed that the Taq-1 VDR variant was more
prevalent in the male CD population compared with
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the female CD population and also in the male IBD,
CD and UC patients compared with the male controls.
The strongest signal in the data came from the male
CD population and whilst the confounding factor of
multiple comparisons must be taken into consider-
ation when undertaking genotype–phenotype analysis,
our data are internally consistent across the disease
groups that were examined. The Taq-1 polymorphism
represents a synonymous T–C base substitution at
codon 352 in exon 8 of the VDR gene and the index
study by Morrison et al. suggested that in vitro the
risk haplotype may be associated with increased gene
transcription.21 Data from Oxford showed more Taq-1
homozygotes in the CD population compared with
controls; however, gender-specific data were not pro-
vided.26 Previous IBD genetic studies using gender
stratification have found male-specific linkage to the
human leukocyte antigen (HLA) region of chromo-
some 6 and no association with the IBD2 locus.35
Although the numbers in both studies are small, the
trends in the data sets are the same and our own
detailed studies of the IBD2 region involving 1400
SNPs and 2024 IBD patients may help resolve this
issue.
In conclusion, our results show relatively low pre-
valence of osteoporosis in a large cohort of Scottish
patients with IBD. Low BMI was the strongest risk
factor associated with osteoporosis. Longitudinal
follow-up studies to assess the benefits of nutritional
intervention in these patients, on BMI, bone density
and fracture risk will be of great interest.
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